Fertility Genomics Division, GeneTech, Hyderabad, India.
J Matern Fetal Neonatal Med. 2022 Dec;35(25):9406-9414. doi: 10.1080/14767058.2022.2038560. Epub 2022 Feb 9.
The biology of recurrent pregnancy loss and recurrent implantation failure (RPL-RIF) is complex with multi-factorial etiology, with defective thrombosis being one of the most important and highly prevalent causes. The role of several thrombophilia related genes and variants associated with RPL-RIF is widely reported, and this study aimed to identify the risk associated with these genes in the Indian population.
Next generation sequencing (NGS) was employed for the current study. NGS enables sequencing of multiple genes, identification of new variants, and establishment of genetic correlations with reproductive failure in diverse population groups. The present NGS based study evaluates association of twenty-nine genotypes of ten coagulation pathway genes (, , , , , , , , and ) with RPL-RIF in 540 female subjects - 474 patients with early recurrent pregnancy loss, late pregnancy loss, pregnancy complications in late gestation and recurrent implantation failure, with 66 controls.
The results emphasize inclusion of genotypes of seven thrombophilia genes (, , , , , , ) for diagnosis of inherited thrombophilia risk for RPL-RIF in Indian population, as against the common practice of testing limited to F2, F5 and MTHFR genes.
Deriving risk magnitude from Combined Risk Analysis and interpretation of high-risk haplotypes are crucial components for evidence based personalized management such as selection of drugs and dosage, and prenatal or pre-implantation recommendations, for high-risk patients in fertility and obstetric clinics.
复发性妊娠丢失(RPL)和复发性种植失败(RIF)的生物学机制复杂,病因多因素,血栓形成缺陷是最重要和最常见的原因之一。许多与血栓形成相关的基因和与 RPL-RIF 相关的变异体的作用已被广泛报道,本研究旨在确定这些基因在印度人群中的风险。
本研究采用下一代测序(NGS)。NGS 可用于测序多个基因,识别新的变异体,并建立与不同人群生殖失败相关的遗传相关性。本基于 NGS 的研究评估了十个凝血途径基因(、、、、、、、和)的二十九种基因型与 540 名女性受试者(474 名早期复发性妊娠丢失、晚期妊娠丢失、晚期妊娠并发症和复发性种植失败患者,66 名对照)中 RPL-RIF 的相关性。
结果强调包括七个血栓形成基因(、、、、、、)的基因型用于诊断印度人群 RPL-RIF 的遗传性血栓形成风险,而不是常见的仅检测 F2、F5 和 MTHFR 基因。
联合风险分析得出的风险幅度和高风险单倍型的解释是生育和产科诊所中高风险患者基于证据的个性化管理(如药物选择和剂量、产前或植入前建议)的关键组成部分。